ClinicalTrials.gg
CompletedNCT00777946Updated Jul 12, 2011Results posted

Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone

A Phase 3 interventional study of Aliskiren 300 mg and Aliskiren/Amlodipine 300/5 mg in Hypertension, sponsored by Novartis. Completed at 9 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-07-12.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
818
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 228 studies in Hypertension by Novartis — 5 open to participants now, 6 under way, none of them phase 3. Hypertension · Novartis.

Enrollment
45th of 223
818 · median 300
Started
2008
with 24 others
Phase 3
108 of 228
none open now
Registered
147th of 228
by date

Among the 228 studies in Hypertension by Novartis, this one is the 45th largest by enrollment of the 223 interventional ones that give a count, is one of 25 that started in 2008, is one of 108 in phase 3, and was the 147th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

5 of the 228 studies in Hypertension by Novartis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 228 studies in Hypertension by Novartis, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of combination aliskiren/amlodipine in patients not adequately controlled with aliskiren alone

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Aliskiren, Amlodipine, Non-responder to aliskiren
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to Visit 1 must have a mean sitting Diastolic Blood Pressure (msDBP) ≥ 95 mmHg and \< 110 mmHg at Visits 1 and 2
  • Patients who have been treated for hypertension within the 4 weeks prior to - Visit 1 must have a msDBP ≥ 90 mmHg and \< 110 mmHg at Visit 2
  • All patients must have a msDBP ≥ 90 mmHg and \< 110 mmHg at Visit 4

Exclusion criteria

Exclusion Criteria:

  • Severe hypertension
  • Pregnant or nursing (lactating) women
  • Women of
  • Previous or current diagnosis of heart failure (NYHA Class II-IV)
  • Serum potassium ≥ 5.3 mEq/L (mmol/L) at Visit 1
  • Uncontrolled Type 1 or Type 2 diabetes mellitus
  • to renin inhibitors, calcium channel blockers, or to drugs with Similar chemical structures
  • History of hypertensive encephalopathy or cerebrovascular accident, or history of (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
818 participants (actual)

Study arms

  • Experimental
    Aliskiren 300 mg/Amlodipine 5 mg

    Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks.

    Drug: Aliskiren/Amlodipine 300/5 mg · Drug: Placebo to Aliskiren

  • Experimental
    Aliskiren 300 mg/Amlodipine 10 mg

    Participants received 1 Aliskiren/Amlodipine 300/10 mg tablet + 1 Placebo to Aliskiren tablet orally once daily in the morning for 8 weeks.

    Drug: Aliskiren/Amlodipine 300/10 mg · Drug: Placebo to Aliskiren

  • Active comparator
    Aliskiren 300 mg

    Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks.

    Drug: Aliskiren 300 mg · Drug: Placebo to Aliskiren/Amlodipine

Interventions

  • DrugAliskirenStudies of AliskirenAliskiren pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Aliskiren 300 mg tablet taken orally once a day with a glass of water.

  • DrugAliskiren/Amlodipine 300/5 mg

    Aliskiren/Amlodipine 300/5 mg tablet taken orally once a day with a glass of water.

  • DrugAliskiren/Amlodipine 300/10 mg

    Aliskiren/Amlodipine 300/10 mg taken orally once a day with a glass of water.

  • DrugPlacebo to Aliskiren

    Placebo to Aliskiren tablet taken orally once a day.

  • DrugPlacebo to Aliskiren/Amlodipine

    Placebo to Aliskiren/Amlodipine taken orally once a day.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to End of Study in the Mean Sitting Diastolic Blood Pressure (msDBP)

    After the patient had been sitting for 5 minutes, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. The difference of the msDBP at baseline from the msDBP at 8 weeks was calculated using an Analysis of Covariance (ANCOVA) model with baseline as a covariate and treatment and region as two factors.

    Time frame: Baseline, End of Study (Week 8)

Secondary outcomes

  1. Change From Baseline to End of Study in the Mean Sitting Systolic Blood Pressure (msSBP)

    After the patient had been sitting for 5 minutes, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. The difference of the msSBP at baseline from the msSBP at 8 weeks was calculated using an ANCOVA model with baseline as a covariate and treatment and region as two factors.

    Time frame: Baseline, End of Study (Week 8)

  2. Number of Participants With Serious Adverse Events and Adverse Events

    The number of participants with any Serious Adverse Event and the number of participants with Adverse Events in any system organ class. Additional information about Adverse Events can be found in the Adverse Event Section.

    Time frame: 8 weeks

  3. Percentage of Participants Achieving Blood Pressure Control

    After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. Blood Pressure control was defined as having a mean sitting Diastolic Blood Pressure \<90 and a mean sitting Systolic Blood Pressure \<140.

    Time frame: 8 weeks

  4. Percentage of Participants Achieving a Diastolic Blood Pressure Response

    After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A Diastolic Blood Pressure Response was defined as a mean sitting Diastolic Blood Pressure (msDBP) \<90 mmHg or a ≥ 10 mmHg reduction in msDBP from baseline.

    Time frame: 8 weeks

  5. Percentage of Participants Achieving a Systolic Blood Pressure Response

    After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A Systolic Blood Pressure Response was defined as a mean sitting Systolic Blood Pressure (msSBP) \<140 mmHg or a ≥ 20 mmHg reduction in msSBP from baseline.

    Time frame: 8 weeks

07

Results

Posted Jun 15, 2011

Participant flow

Participant flow — Overall Study
MilestoneAliskiren 300 mg/Amlodipine 10 mgAliskiren 300 mg/Amlodipine 5 mgAliskiren 300 mg
Started283277260
Safety & full analysis sets282276260
Completed262271244
Not completed21616
Withdrew: Adverse event1113
Withdrew: Lack of efficacy009
Withdrew: Condition no longer required study drug100
Withdrew: Patient withdrew consent323
Withdrew: Lost to follow-up310
Withdrew: Protocol deviation211
Withdrew: Randomized in error110

Outcome measures

PrimaryChange From Baseline to End of Study in the Mean Sitting Diastolic Blood Pressure (msDBP)

After the patient had been sitting for 5 minutes, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. The difference of the msDBP at baseline from the msDBP at 8 weeks was calculated using an Analysis of Covariance (ANCOVA) model with baseline as a covariate and treatment and region as two factors.

Time frame:
Baseline, End of Study (Week 8)
Reported as:
Least squares mean · mm Hg
Change From Baseline to End of Study in the Mean Sitting Diastolic Blood Pressure (msDBP)
mm HgAliskiren 300 mg/Amlodipine 10 mgAliskiren 300 mg/Amlodipine 5 mgAliskiren 300 mg
Change From Baseline to End of Study in the Mean Sitting Diastolic Blood Pressure (msDBP)-13.07 ± 0.463-10.54 ± 0.467-5.84 ± 0.480
SecondaryChange From Baseline to End of Study in the Mean Sitting Systolic Blood Pressure (msSBP)

After the patient had been sitting for 5 minutes, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. The difference of the msSBP at baseline from the msSBP at 8 weeks was calculated using an ANCOVA model with baseline as a covariate and treatment and region as two factors.

Time frame:
Baseline, End of Study (Week 8)
Reported as:
Least squares mean · mm Hg
Change From Baseline to End of Study in the Mean Sitting Systolic Blood Pressure (msSBP)
mm HgAliskiren 300 mg/Amlodipine 10 mgAliskiren 300 mg/Amlodipine 5 mgAliskiren 300 mg
Change From Baseline to End of Study in the Mean Sitting Systolic Blood Pressure (msSBP)-18.04 ± 0.780-14.43 ± 0.788-6.42 ± 0.809
SecondaryNumber of Participants With Serious Adverse Events and Adverse Events

The number of participants with any Serious Adverse Event and the number of participants with Adverse Events in any system organ class. Additional information about Adverse Events can be found in the Adverse Event Section.

Time frame:
8 weeks
Reported as:
Number · participants
Number of Participants With Serious Adverse Events and Adverse Events
participantsAliskiren 300 mg/Amlodipine 10 mgAliskiren 300 mg/Amlodipine 5 mgAliskiren 300 mg
Serious Adverse Events341
Adverse Events858059
SecondaryPercentage of Participants Achieving Blood Pressure Control

After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. Blood Pressure control was defined as having a mean sitting Diastolic Blood Pressure \<90 and a mean sitting Systolic Blood Pressure \<140.

Time frame:
8 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Blood Pressure Control
Percentage of participantsAliskiren 300 mg/Amlodipine 10 mgAliskiren 300 mg/Amlodipine 5 mgAliskiren 300 mg
Percentage of Participants Achieving Blood Pressure Control65.556.531.5
SecondaryPercentage of Participants Achieving a Diastolic Blood Pressure Response

After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A Diastolic Blood Pressure Response was defined as a mean sitting Diastolic Blood Pressure (msDBP) \<90 mmHg or a ≥ 10 mmHg reduction in msDBP from baseline.

Time frame:
8 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Diastolic Blood Pressure Response
Percentage of participantsAliskiren 300 mg/Amlodipine 10 mgAliskiren 300 mg/Amlodipine 5 mgAliskiren 300 mg
Percentage of Participants Achieving a Diastolic Blood Pressure Response83.677.751.5
SecondaryPercentage of Participants Achieving a Systolic Blood Pressure Response

After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A Systolic Blood Pressure Response was defined as a mean sitting Systolic Blood Pressure (msSBP) \<140 mmHg or a ≥ 20 mmHg reduction in msSBP from baseline.

Time frame:
8 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Systolic Blood Pressure Response
Percentage of participantsAliskiren 300 mg/Amlodipine 10 mgAliskiren 300 mg/Amlodipine 5 mgAliskiren 300 mg
Percentage of Participants Achieving a Systolic Blood Pressure Response77.269.743.8

Adverse events

Collected over 8 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aliskiren 300 mg/Amlodipine 10 mg—3/282 (1.1%)26/282 (9.2%)
Aliskiren 300 mg/Amlodipine 5 mg—4/276 (1.4%)6/276 (2.2%)
Aliskiren 300 mg—1/260 (0.4%)1/260 (0.4%)
Most frequent serious events
Most frequent serious events
EventAliskiren 300 mg/Amlodipine 10 mgAliskiren 300 mg/Amlodipine 5 mgAliskiren 300 mg
Post-traumatic painInjury, poisoning and procedural complications0/2820/2761/260
Road traffic accidentInjury, poisoning and procedural complications0/2820/2761/260
VertigoEar and labyrinth disorders0/2821/2760/260
PyrexiaGeneral disorders0/2821/2760/260
Viral infectionInfections and infestations0/2821/2760/260
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2821/2760/260
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/2821/2760/260
Drug hypersensitivityImmune system disorders1/2820/2760/260
Lobar pneumoniaInfections and infestations1/2820/2760/260
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/2820/2760/260
Most frequent other events
Most frequent other events
EventAliskiren 300 mg/Amlodipine 10 mgAliskiren 300 mg/Amlodipine 5 mgAliskiren 300 mg
Oedema peripheralGeneral disorders26/2826/2761/260

Baseline characteristics

Age Continuous
Age Continuous(years)Aliskiren 300 mg/Amlodipine 10 mgAliskiren 300 mg/Amlodipine 5 mgAliskiren 300 mgTotal
Mean54.6 ± 10.6754.4 ± 10.6954.7 ± 10.9954.6 ± 10.77
Sex: Female, Male
Sex: Female, Male(Participants)Aliskiren 300 mg/Amlodipine 10 mgAliskiren 300 mg/Amlodipine 5 mgAliskiren 300 mgTotal
Female120101103324
Male163176157496
08

Study locations

9 sites
  • Investigative site
    Estonia, Estonia
  • Investigative site
    France, France
  • Investigative Site
    Iceland, Iceland
  • Investigative Site
    India, India
  • Investigative site
    Italy, Italy
  • Investigative Site
    Republic of Korea, Korea, Republic of
  • Investigative Site
    Lithuania, Lithuania
  • Investigative Site
    Spain, Spain
  • Investigative Site
    Venezuela, Venezuela
09

References and documents

Publications

  • Glorioso N, Thomas M, Troffa C, Argiolas G, Patel S, Baek I, Zhang J. Antihypertensive efficacy and tolerability of aliskiren/amlodipine single- pill combinations in patients with an inadequate response to aliskiren monotherapy. Curr Vasc Pharmacol. 2012 Nov;10(6):748-55. doi: 10.2174/157016112803520765. PubMed 22303910 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2008
First posted
Oct 22, 2008
Start
Oct 2008
Primary completionActual
May 2009
CompletionActual
May 2009
Results first posted
Jun 15, 2011
Last update
Jul 12, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00777946
Lead sponsor
Novartis
First posted
Oct 22, 2008
Start date
Oct 2008
Primary completion
May 2009
Completion
May 2009
Results posted
Jun 15, 2011
Last update
Jul 12, 2011

Study contacts

Novartis
study chair · Novartis

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion